Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative

Rhea-AI Summary

Jin Medical International (NASDAQ: ZJYL) announced a 1-for-20 share combination and share class reclassification effective March 16, 2026 at 09:00 a.m. ET. The reclassification creates 45,000,000 Class A and 5,000,000 Class B authorized shares (par value US$0.001).

Issued Class A shares will consolidate from 136,547,100 to 6,827,355 and Class B from 20,000,000 to 1,000,000; new Class A CUSIP is G5140V120. The company says the move aims to support Nasdaq continued-listing compliance and strengthen long-term capital structure.

Positive

• 1-for-20 share combination effective March 16, 2026
• Issued Class A shares reduced to 6,827,355
• Issued Class B shares reduced to 1,000,000
• New Class A CUSIP: G5140V120
• Company cites objective to maintain Nasdaq compliance and strengthen capital structure

Negative

• Consolidation reduces outstanding float roughly 20-fold, potentially lowering trading liquidity
• Trading will reflect consolidation-adjusted share count when markets open on March 16, 2026

News Market Reaction – ZJYL

-18.34% 3.0x vol

10 alerts

-18.34% News Effect

-31.3% Trough in 28 hr 28 min

-$6M Valuation Impact

$25.05M Market Cap

3.0x Rel. Volume

On the day this news was published, ZJYL declined 18.34%, reflecting a significant negative market reaction. Argus tracked a trough of -31.3% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $25.05M at that time. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share combination ratio: 1-for-20 Authorized share capital: US$50,000 Authorized Class A shares: 45,000,000 shares +5 more

8 metrics

Share combination ratio 1-for-20 Reverse share combination of all authorized and issued ordinary shares

Authorized share capital US$50,000 Total authorized share capital after reclassification and combination

Authorized Class A shares 45,000,000 shares Class A ordinary shares authorized post-reclassification

Authorized Class B shares 5,000,000 shares Class B ordinary shares authorized post-reclassification

Par value US$0.001 Par value per Class A and Class B ordinary share after changes

Class A shares pre-combination 136,547,100 shares Issued and outstanding Class A ordinary shares before stock combination

Class A shares post-combination 6,827,355 shares Issued and outstanding Class A ordinary shares after stock combination

Class B shares post-combination 1,000,000 shares Issued and outstanding Class B ordinary shares after stock combination

Market Reality Check

Price: $2.02 Vol: Volume 1,294,267 is 4.11x...

high vol

$2.02 Last Close

Volume Volume 1,294,267 is 4.11x the 20-day average of 314,579, signaling elevated trading interest ahead of the share combination. high

Technical Shares trade below the 200-day MA of 0.43 at 0.1423, sitting close to the 52-week low of 0.11 and far from the 52-week high of 1.025.

Peers on Argus

Peer moves are mixed: ZTEK -1.42%, PDEX +2.06%, AVR +0.60%, KRMD 0%, UTMD -0.03%...

Peer moves are mixed: ZTEK -1.42%, PDEX +2.06%, AVR +0.60%, KRMD 0%, UTMD -0.03%. With no broad momentum flags and minimal same-day peer news, the stock combination announcement appears primarily company-specific rather than a sector-driven move.

Historical Context

4 past events · Latest: Feb 05 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	CEO fireside chat	Positive	+1.6%	CEO outlined strategic priorities and reverse split framework to investors.
Jan 26	Fireside chat notice	Positive	+4.8%	Announcement of management fireside chat on growth and strategy.
Jan 22	Facility milestone	Positive	+3.2%	Chuzhou facility cleared for Class I devices with 200,000-unit capacity.
Jan 21	Capital structure talk	Positive	-4.1%	Planned chat on strategic priorities and capital structure considerations.

Pattern Detected

Recent strategic and operational updates have usually seen modest positive price reactions, while one capital-structure-focused communication coincided with a negative move.

Recent Company History

Over recent months, Jin Medical has focused on strategic communication and manufacturing expansion. Updates on the Chuzhou facility’s ramp and capacity of 200,000 units supported positive price reactions. Multiple fireside chats outlined capital structure plans, including potential reverse splits, with generally constructive stock responses except a Jan 21, 2026 update that saw a decline. Today’s share combination fits this ongoing capital structure realignment alongside growth investments.

Regulatory & Risk Context

Active S-3 Shelf · $300 million

Shelf Active

Active S-3 Shelf Registration 2025-06-25

$300 million registered capacity

An effective Form F-3 universal shelf filed on 2025-06-25 allows Jin Medical to offer up to $300 million in securities over time, providing flexibility for future capital raises and creating potential dilution when utilized.

Market Pulse Summary

The stock dropped -18.3% in the session following this news. A negative reaction despite a planned s...

Analysis

The stock dropped -18.3% in the session following this news. A negative reaction despite a planned share combination would fit concerns often seen around reverse splits and governance changes. The stock previously traded far below the 200-day MA and close to its 52-week low, so sentiment was already fragile. Investors would need to monitor how the new dual-class structure, potential future offerings under the $300 million shelf, and operational milestones affect confidence.

Key Terms

share combination, dual class, par value, memorandum and articles of association, +2 more

6 terms

share combination financial

"approved an 1-for-20 share combination of all its authorized and issued ordinary shares"

A share combination is when a company reduces the number of its outstanding shares by consolidating multiple existing shares into a smaller number of new shares (for example, combining 10 old shares into 1 new share). For investors it raises the stock price per share without changing the company’s overall value, like exchanging ten pennies for one dime; it can affect trading liquidity, index eligibility and investor perception even though ownership percentage stays the same.

dual class financial

"authorized share capital is reclassified into a dual class of Class A ordinary shares and Class B"

A dual class share structure is when a company issues two (or more) types of stock that look similar financially but give different voting power; one class carries stronger control over corporate decisions while the other carries ordinary economic rights like dividends. For investors this matters because it can concentrate decision-making in the hands of a few people — like owning seats at a driver’s wheel while others ride in the back — which affects influence over strategy, takeover chances, and how shareholder interests are protected.

par value financial

"Class A ordinary shares of a par value of US$0.001 each, and 5,000,000 Class B"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

memorandum and articles of association regulatory

"filed the second amended and restated memorandum and articles of association"

Memorandum and articles of association are the founding legal documents of a company: the memorandum sets out the company’s basic purpose and scope, while the articles act as its internal rulebook detailing how the company is run, who has what powers, and how decisions are made. For investors these documents matter because they define ownership rights, voting rules, limits on activities, and procedures for major changes—like a contract and rulebook that determine how their investment can be used and protected.

cusip technical

"The new CUSIP number for the Class A ordinary shares following the Stock Combination"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

nasdaq capital market financial

"Class A ordinary shares will continue to trade on The Nasdaq Capital Market ("Nasdaq")"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. Not financial advice.

CHANGZHOU, China, March 11, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that its Board of Directors has approved an 1-for-20 share combination of all its authorized and issued ordinary shares (the "Stock Combination") pursuant to the authorization granted from an extraordinary general meeting of the Company's shareholders on January 30, 2026 (the "EGM"). Effective as of the date of the EGM, the Company's authorized share capital is reclassified into a dual class of Class A ordinary shares and Class B ordinary shares (the "Reclassification"). As a result of the Reclassification and the Stock Combination, the Company's authorized share capital will be US$50,000 divided into 45,000,000 Class A ordinary shares of a par value of US$0.001 each, and 5,000,000 Class B ordinary shares of a par value of US$0.001 each. In accordance with the requirements under Cayman Islands law, the Company has filed the second amended and restated memorandum and articles of association with the Registrar of Companies in the Cayman Islands to reflect the Reclassification. The Company has also filed the EGM minutes along with the board resolutions approving the Stock Combination with the Registrar of Companies in the Cayman Islands to effectuate the Stock Combination.

The Stock Combination will become effective on March 16, 2026 at 09:00 a.m., Eastern Time.

The Company's Class A ordinary shares will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the existing symbol "ZJYL" and will begin trading on a consolidation-adjusted basis when the market opens on March 16, 2026. The new CUSIP number for the Class A ordinary shares following the Stock Combination will be G5140V120.

At the effective time of the Stock Combination, every 20 shares of the Company's authorized and issued ordinary shares (including all Class A ordinary shares and Class B ordinary shares) will be combined into 1 share of ordinary share in the respective share class. This will reduce the number of issued and outstanding shares of Class A ordinary shares from 136,547,100 shares to 6,827,355 shares, and reduce the number of issued and outstanding shares of Class B ordinary shares from 20,000,000 shares to 1,000,000 shares.

The Company believes the Stock Combination is a proactive measure as part of the Company's strategic plan to maintain compliance with Nasdaq's continued listing requirements, while it is also intended for strengthening the Company's long-term capital structure. 

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical's wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "should", "intend", "plan", "strive", "believe", "expect", "anticipate", "project", "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company's ability to achieve its goals and strategies, the Company's future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission ("SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
ir@jinmed.com

View original content:https://www.prnewswire.com/news-releases/jin-medical-international-ltd-announces-1-for-20-share-combination-as-part-of-strategic-nasdaq-compliance-initiative-302711269.html

SOURCE Jin Medical International Ltd.

FAQ

What is the 1-for-20 share combination for Jin Medical (ZJYL) and when is it effective?

The 1-for-20 share combination consolidates every 20 shares into 1 and is effective March 16, 2026 at 09:00 a.m. ET. According to the company, trading will reflect the consolidation-adjusted basis when Nasdaq opens on that date.

How many Class A and Class B shares will Jin Medical (ZJYL) have after the March 16, 2026 consolidation?

After the consolidation, Class A issued shares will be 6,827,355 and Class B issued shares will be 1,000,000. According to the company, authorized capital will be reclassified to 45,000,000 Class A and 5,000,000 Class B shares.

Will Jin Medical (ZJYL) keep the same ticker and is there a new CUSIP after the consolidation?

Jin Medical will continue trading under the existing ticker ZJYL and will trade on a consolidation-adjusted basis on March 16, 2026. According to the company, the new Class A CUSIP is G5140V120.

Why did Jin Medical (ZJYL) approve the share consolidation and reclassification?

The company says the consolidation is a proactive measure to maintain Nasdaq continued-listing compliance and to strengthen its long-term capital structure. According to the company, the EGM on January 30, 2026 authorized the actions.

How will the March 16, 2026 share consolidation affect existing shareholders of ZJYL?

Each shareholder will hold one consolidated share for every 20 pre-consolidation shares, leaving proportional ownership unchanged. According to the company, issued and outstanding counts will be adjusted to the new Class A and Class B totals on the effective date.